{"id":3799,"date":"2021-04-06T10:52:38","date_gmt":"2021-04-06T14:52:38","guid":{"rendered":"https:\/\/aqcamo.ca\/formations\/"},"modified":"2026-08-02T21:42:17","modified_gmt":"2026-08-03T01:42:17","slug":"education","status":"publish","type":"page","link":"https:\/\/aqcamo.ca\/en\/education\/","title":{"rendered":"Education"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.16&#8243; custom_margin=&#8221;|auto||372px||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.16&#8243; min_height=&#8221;56px&#8221; custom_padding=&#8221;20px||2px|||&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4 style=\"text-align: right;\"><span style=\"font-size: x-large;\"><em>Please note that all presentations are in french.<\/em><\/span><\/h4>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2>Conferences<\/h2>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_2,1_2&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/aqcamo.ca\/wp-content\/uploads\/2021\/04\/Visuel-conference-scaled.jpg&#8221; url=&#8221;https:\/\/aqcamo.ca\/courses\/gestion-du-temps-et-des-priorites-un-defi-un-atout\/&#8221; url_new_window=&#8221;on&#8221; _builder_version=&#8221;4.16&#8243; width=&#8221;100%&#8221; module_alignment=&#8221;center&#8221; custom_padding=&#8221;|0px|0px|||&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/aqcamo.ca\/wp-content\/uploads\/2021\/04\/Titre-CP-scaled.jpg&#8221; url=&#8221;https:\/\/aqcamo.ca\/courses\/capsules-partenaires\/&#8221; url_new_window=&#8221;on&#8221; disabled_on=&#8221;on|on|on&#8221; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;||12px|||&#8221; disabled=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2>Webinars<\/h2>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; column_structure=&#8221;1_3,1_3,1_3&#8243;][et_pb_column _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; type=&#8221;1_3&#8243;][et_pb_code _builder_version=&#8221;4.27.4&#8243; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<div style=\"padding:56.25% 0 0 0;position:relative;\"><iframe src=\"https:\/\/player.vimeo.com\/video\/1215052822?title=0&amp;byline=0&amp;portrait=0&amp;badge=0&amp;autopause=0&amp;player_id=0&amp;app_id=58479\" frameborder=\"0\" allow=\"autoplay; fullscreen; picture-in-picture; clipboard-write; encrypted-media; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" style=\"position:absolute;top:0;left:0;width:100%;height:100%;\" title=\"Pluvicto Patient Journey_07\"><\/iframe><\/div>\n<p><script src=\"https:\/\/player.vimeo.com\/api\/player.js\"><\/script><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->[\/et_pb_code][\/et_pb_column][et_pb_column _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; type=&#8221;1_3&#8243;][\/et_pb_column][et_pb_column _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; type=&#8221;1_3&#8243;][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_3,1_3,1_3&#8243; _builder_version=&#8221;4.16&#8243; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_code _builder_version=&#8221;4.19.5&#8243; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<iframe loading=\"lazy\" src=\"https:\/\/player.vimeo.com\/video\/802852557?h=99c9fc8523&#038;badge=0&#038;autopause=0&#038;player_id=0&#038;app_id=58479\" width=\"1920\" height=\"1020\" frameborder=\"0\" allow=\"autoplay; fullscreen; picture-in-picture\" allowfullscreen title=\"Capsule Knight.mp4\"><\/iframe>[\/et_pb_code][et_pb_text _builder_version=&#8221;4.19.5&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><em><strong>Pr\u00e9sentation de Knight et de leurs produits en oncologie<\/strong><\/em><\/h4>\n<p>Presented March 27, 2021<br \/>By Knight<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_code _builder_version=&#8221;4.19.5&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<iframe loading=\"lazy\" src=\"https:\/\/player.vimeo.com\/video\/681517177?h=f9a40be676&#038;title=0&#038;byline=0&#038;portrait=0&#038;speed=0&#038;badge=0&#038;autopause=0&#038;player_id=0&#038;app_id=58479\" width=\"1920\" height=\"1080\" frameborder=\"0\" allow=\"autoplay; fullscreen; picture-in-picture\" allowfullscreen title=\"Calsule Pfizer\"><\/iframe>[\/et_pb_code][et_pb_text _builder_version=&#8221;4.19.5&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><em><strong>Processus d&#8217;approbation et de remboursement des m\u00e9dicaments en oncologie au Canada<\/strong><\/em><\/h4>\n<p>Presented March 27, 2021<br \/>By Pfizer<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_code _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;]<iframe loading=\"lazy\" src=\"https:\/\/player.vimeo.com\/video\/566636672?h=69cfb50ad4&#038;badge=0&#038;autopause=0&#038;player_id=0&#038;app_id=58479\" width=\"1920\" height=\"1080\" frameborder=\"0\" allow=\"autoplay; fullscreen; picture-in-picture\" allowfullscreen title=\"Formation EMD Serono\"><\/iframe>[\/et_pb_code][et_pb_text _builder_version=&#8221;4.19.5&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><em><strong>Bavencio (avelumab) en cancer de la vessie<\/strong><\/em><\/h4>\n<p>Presented April 6, 2021<br \/>By EMD Serono<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_3,1_3,1_3&#8243; _builder_version=&#8221;4.16&#8243; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_code _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;]<iframe loading=\"lazy\" src=\"https:\/\/player.vimeo.com\/video\/566631195?h=0ed087a1ec&#038;badge=0&#038;autopause=0&#038;player_id=0&#038;app_id=58479\" width=\"1920\" height=\"1080\" frameborder=\"0\" allow=\"autoplay; fullscreen; picture-in-picture\" allowfullscreen title=\"webinaire du 14 mai - Viatris\"><\/iframe>[\/et_pb_code][et_pb_text _builder_version=&#8221;4.19.5&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><em><strong>La Neutrop\u00e9nie F\u00e9brile \u2013 Un aper\u00e7u<\/strong><\/em><\/h4>\n<p>Presented May 14, 2021<br \/>By Viatris<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_code _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;]<iframe loading=\"lazy\" src=\"https:\/\/player.vimeo.com\/video\/681600461?h=eef2e9608f&#038;badge=0&#038;autopause=0&#038;player_id=0&#038;app_id=58479\" width=\"960\" height=\"540\" frameborder=\"0\" allow=\"autoplay; fullscreen; picture-in-picture\" allowfullscreen title=\"Meeting-20211005_164856-Meeting Recording\"><\/iframe>[\/et_pb_code][et_pb_text _builder_version=&#8221;4.19.5&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><strong>Presentation of the Leukemia &amp; Lymphoma Society of Canada<\/strong><\/h4>\n<p>Presented October 5, 2021<br \/>By the Leukemia &amp; Lymphoma Society of Canada and Abbvie<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_code _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;]<iframe loading=\"lazy\" src=\"https:\/\/player.vimeo.com\/video\/681603689?h=d9428e833c&#038;badge=0&#038;autopause=0&#038;player_id=0&#038;app_id=58479\" width=\"960\" height=\"540\" frameborder=\"0\" allow=\"autoplay; fullscreen; picture-in-picture\" allowfullscreen title=\"Meeting-20211117_235618-Meeting Recording\"><\/iframe>[\/et_pb_code][et_pb_text _builder_version=&#8221;4.19.5&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><em><strong>Programmes d&#8217;acc\u00e8s de BMS pour les cancers digestifs sup\u00e9rieurs<\/strong><\/em><\/h4>\n<p>Presented November 17, 2021<br \/>By Bristol Myers Squibb<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_3,1_3,1_3&#8243; _builder_version=&#8221;4.16&#8243; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_code _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;]<iframe loading=\"lazy\" src=\"https:\/\/player.vimeo.com\/video\/697138730?h=dcf9731307&#038;title=0&#038;byline=0&#038;portrait=0&#038;speed=0&#038;badge=0&#038;autopause=0&#038;player_id=0&#038;app_id=58479\" width=\"1920\" height=\"1080\" frameborder=\"0\" allow=\"autoplay; fullscreen; picture-in-picture\" allowfullscreen title=\"Webinaire Pfizer - Braftovi Mektovi - Programme de support aux patients et nouveau SMART Enrolment\"><\/iframe>[\/et_pb_code][et_pb_text _builder_version=&#8221;4.19.5&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><em><strong>Revue du PSP pour Braftovi et Mektvi<\/strong><\/em><\/h4>\n<p>Presented November 18, 2021<br \/>By Pfizer<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_code _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;]<iframe loading=\"lazy\" src=\"https:\/\/player.vimeo.com\/video\/681439617?h=ee46edcfa7&#038;badge=0&#038;autopause=0&#038;player_id=0&#038;app_id=58479\" width=\"1920\" height=\"1080\" frameborder=\"0\" allow=\"autoplay; fullscreen; picture-in-picture\" allowfullscreen title=\"JAZZPH~1\"><\/iframe>[\/et_pb_code][et_pb_text _builder_version=&#8221;4.19.5&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><em><strong>Nouveaut\u00e9 dans le traitement de seconde intention du cancer du poumon \u00e0 petites cellules<\/strong><\/em><\/h4>\n<p>Presented\u00a0 January 11, 2022<br \/>By Jazz Pharmaceuticals<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_code _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;]<iframe loading=\"lazy\" src=\"https:\/\/player.vimeo.com\/video\/681438582?h=bf68bf9d3f&#038;badge=0&#038;autopause=0&#038;player_id=0&#038;app_id=58479\" width=\"1920\" height=\"1080\" frameborder=\"0\" allow=\"autoplay; fullscreen; picture-in-picture\" allowfullscreen title=\"APOBIO~1\"><\/iframe>[\/et_pb_code][et_pb_text _builder_version=&#8221;4.19.5&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><em><strong>Pr\u00e9sentation et d\u00e9monstration du programme ApoSecure<\/strong><\/em><\/h4>\n<p>Presented January 13, 2022<br \/>By Apotex<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_3,1_3,1_3&#8243; _builder_version=&#8221;4.16&#8243; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_code _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;]<iframe loading=\"lazy\" src=\"https:\/\/player.vimeo.com\/video\/684008339?h=5603c6a6bb&#038;badge=0&#038;autopause=0&#038;player_id=0&#038;app_id=58479\" width=\"1920\" height=\"1080\" frameborder=\"0\" allow=\"autoplay; fullscreen; picture-in-picture\" allowfullscreen title=\"Nouvelle approche th\u00e9rapeutique en LMA : Vyxeos, formulation liposomale\"><\/iframe>[\/et_pb_code][et_pb_text _builder_version=&#8221;4.19.5&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><em><strong>Nouvelle approche th\u00e9rapeutique en LMA : Vyxeos, formulation liposomale<\/strong><\/em><\/h4>\n<p>Presented March 2, 2022<br \/>By Jazz Pharmaceuticals<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_code _builder_version=&#8221;4.17.4&#8243; global_colors_info=&#8221;{}&#8221;]<iframe loading=\"lazy\" src=\"https:\/\/player.vimeo.com\/video\/722191926?h=cf0a43132c&#038;badge=0&#038;autopause=0&#038;player_id=0&#038;app_id=58479\" width=\"1280\" height=\"720\" frameborder=\"0\" allow=\"autoplay; fullscreen; picture-in-picture\" allowfullscreen title=\"Nouveaux traitements dans le lymphome diffus \u00e0 grandes cellules B (LDGCB) r\u00e9cidivant ou r\u00e9fractaire\"><\/iframe>[\/et_pb_code][et_pb_text _builder_version=&#8221;4.19.5&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><em><strong>Nouveaux traitements dans le lymphome diffus \u00e0 grandes cellules B (LDGCB) r\u00e9cidivant ou r\u00e9fractaire<\/strong><\/em><\/h4>\n<p>Presented June 15, 2022<br \/>By Incyte<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_code _builder_version=&#8221;4.17.4&#8243; global_colors_info=&#8221;{}&#8221;]<iframe loading=\"lazy\" src=\"https:\/\/player.vimeo.com\/video\/724523382?h=6694a8dcdb&#038;badge=0&#038;autopause=0&#038;player_id=0&#038;app_id=58479\" width=\"1280\" height=\"720\" frameborder=\"0\" allow=\"autoplay; fullscreen; picture-in-picture\" allowfullscreen title=\"Pr\u00e9sentation sur le programme MyBeiGene aux coordonnateurs pour l\u2019acc\u00e8s aux m\u00e9dicaments\"><\/iframe>[\/et_pb_code][et_pb_text _builder_version=&#8221;4.19.5&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><strong>Presentation on the MyBeiGene program to drug access navigators<\/strong><\/h4>\n<p>Presented June 20, 2022<br \/>By BeiGene<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_3,1_3,1_3&#8243; _builder_version=&#8221;4.16&#8243; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_code _builder_version=&#8221;4.18.0&#8243; global_colors_info=&#8221;{}&#8221;]<iframe loading=\"lazy\" src=\"https:\/\/player.vimeo.com\/video\/757587753?h=84851fcc72&#038;badge=0&#038;autopause=0&#038;player_id=0&#038;app_id=58479\" width=\"1280\" height=\"720\" frameborder=\"0\" allow=\"autoplay; fullscreen; picture-in-picture\" allowfullscreen title=\"MERCK SANT\u00c9\u2122 Oncologie \u2013 Inscriptions et Indications\"><\/iframe>[\/et_pb_code][et_pb_text _builder_version=&#8221;4.19.5&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><em><strong>MERCK SANT\u00c9\u2122 Oncologie \u2013 Inscriptions et Indications<\/strong><\/em><\/h4>\n<p>Presented October 5, 2022<br \/>By Merck<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_code _builder_version=&#8221;4.18.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<iframe loading=\"lazy\" src=\"https:\/\/player.vimeo.com\/video\/768712802?h=5b96a62948&#038;badge=0&#038;autopause=0&#038;player_id=0&#038;app_id=58479\" width=\"1280\" height=\"720\" frameborder=\"0\" allow=\"autoplay; fullscreen; picture-in-picture\" allowfullscreen title=\"BMS - Mise \u00e0 jour sur le remboursement public pour Azacitidine\/ Onureg et Fedratinib\/ Inrebic et programmes patients associ\u00e9s\"><\/iframe>[\/et_pb_code][et_pb_text _builder_version=&#8221;4.19.5&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><em><strong>Mise \u00e0 jour sur le remboursement public pour Azacitidine\/ Onureg et Fedratinib\/ Inrebic et programmes patients associ\u00e9s<\/strong><\/em><\/h4>\n<p>Presented November 1, 2022<br \/>By Bristol Myers Squibb<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_code _builder_version=&#8221;4.19.5&#8243; _module_preset=&#8221;default&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<iframe loading=\"lazy\" src=\"https:\/\/player.vimeo.com\/video\/804080220?h=91dd10a369&#038;title=0&#038;byline=0&#038;portrait=0&#038;speed=0&#038;badge=0&#038;autopause=0&#038;player_id=0&#038;app_id=58479\" width=\"1280\" height=\"720\" frameborder=\"0\" allow=\"autoplay; fullscreen; picture-in-picture\" allowfullscreen title=\"\u00ab MERCK SANT\u00c9\u2122 Oncologie \u2013 Ajout au Programme \u00bb pr\u00e9sent\u00e9 le 28 f\u00e9vrier 2023 par Merck\"><\/iframe>[\/et_pb_code][et_pb_text _builder_version=&#8221;4.19.5&#8243; _module_preset=&#8221;default&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><em><strong>MERCK SANT\u00c9\u2122 Oncologie \u2013 Ajout au Programme<\/strong><\/em><\/h4>\n<p>Presented February 28, 2023<br \/>By Merck<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2>Training<\/h2>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_3,1_3,1_3&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/aqcamo.ca\/wp-content\/uploads\/2021\/08\/Pages-de-AQCAMO_Training-program_version-courte-scaled.jpg&#8221; url=&#8221;https:\/\/aqcamo.ca\/wp-content\/uploads\/2021\/08\/AQCAMO_Training-program_version-courte.pdf&#8221; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Please note that all presentations are in french&#8230;.<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-3799","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/aqcamo.ca\/en\/wp-json\/wp\/v2\/pages\/3799","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aqcamo.ca\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/aqcamo.ca\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/aqcamo.ca\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/aqcamo.ca\/en\/wp-json\/wp\/v2\/comments?post=3799"}],"version-history":[{"count":28,"href":"https:\/\/aqcamo.ca\/en\/wp-json\/wp\/v2\/pages\/3799\/revisions"}],"predecessor-version":[{"id":12772,"href":"https:\/\/aqcamo.ca\/en\/wp-json\/wp\/v2\/pages\/3799\/revisions\/12772"}],"wp:attachment":[{"href":"https:\/\/aqcamo.ca\/en\/wp-json\/wp\/v2\/media?parent=3799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}